Why is Tirzepatide banned in the Chinese market?

As of now (2025), Tirzepatide (Tirzepatide) has not been officially marketed in mainland China. It is not "banned", but is still in the approval or evaluation stage. The drug was developed by Eli Lilly (Eli Lilly) and was originally used to treat type 2 diabetes. Later, due to its significant weight loss effect, it was also widely concerned for obesity management. However, China's drug regulatory authorities have strict approval procedures for new drugs, including local clinical trials, drug safety and effectiveness evaluation, etc. Therefore, even if the drug has been approved abroad, it will still take some time to be launched in China.

On the other hand, although tilsiparatide has been approved for weight loss or diabetes treatment in the European and American markets, its long-term safety still requires further observation. Chinese regulatory authorities tend to adopt a more prudent attitude when it comes to the introduction of new drugs, especially those involving long-term use such as weight management. During the domestic review process, the cardiovascular risk, side effect data, and compatibility of the drug with the local population are all key considerations. Therefore, there is no so-called "ban", but the regulatory process has not been completely completed.

It is worth noting that tilsiparatide has triggered a huge weight loss trend in overseas markets, and many domestic consumers also obtain the drug through purchasing agents or going abroad for medical treatment. However, since it has not yet been approved for marketing in China, there are certain legal and medication risks in these channels. Drugs have not been approved by the State Food and Drug Administration, are not supported by medical insurance, and lack systematic medical supervision. Patients may have adverse reactions during use and cannot receive timely and standardized treatment.

In summary, tilsiparatide is not banned in China due to safety issues but because it is still in the review stage before the drug is put on the market. At present, if domestic patients need to use it, they can only obtain it through overseas channels, but this also means that they must bear higher medication risks and economic costs. It is expected that with the subsequent accumulation of data and the advancement of the approval process, the drug may be officially launched in the Chinese market in the future.

Reference materials:https://www.drugs.com/tirzepatide.html